Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Neurol India ; 71(6): 1132-1141, 2023.
Article in English | MEDLINE | ID: mdl-38174446

ABSTRACT

Background: Disease-modifying agents like Pioglitazone have shown promising effects on neuroinflammation and homeostasis of amyloid plaques, but there is a lack of research papers providing conclusive evidence. Objectives: This study is aimed to determine the safety and efficacy of Pioglitazone in improving cognitive function in patients with mild-moderate Alzheimer's disease (AD). Materials and Methods: Trials published in the last 12 years were identified from PubMed, Scopus, Cochrane Central, and other trial registries. Five hundred twenty-five records were obtained, from which five studies were included for quantitative analysis. Studies comparing Pioglitazone with a suitable placebo or other oral hypoglycemic agent were considered for review. Data was extracted using a pretested form, which was followed by a risk of bias assessment (ROB) with Cochrane's ROB assessment tool. Results: This meta-analysis included studies where Pioglitazone (15-30 mg) was compared to other oral hypoglycemic agents, placebo, or diabetic diet for a minimum duration of 6 months. Pioglitazone did not show a statistically significant improvement in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores [mean difference (MD): -1.16; 95% confidence interval (CI): -4.14-1.81]. By conducting sensitivity analysis with the removal of one study, significant efficacy was obtained [MD: -2.75; 95% CI: -4.84--0.66]. The Wechsler Memory Scale-Revised logical memory I (WMS-R) scores had a significant improvement in the Pioglitazone group [MD: 2.02; 95% CI: 0.09-3.95]. Conclusion: Pioglitazone is a safe medication that has a promising effect in slowing the advancement of AD.


Subject(s)
Alzheimer Disease , Humans , Alzheimer Disease/drug therapy , Pioglitazone/therapeutic use , Pioglitazone/pharmacology , Drug Repositioning , Cognition
2.
Contrast Media Mol Imaging ; 2017: 7498538, 2017.
Article in English | MEDLINE | ID: mdl-29097936

ABSTRACT

Molecular magnetic resonance imaging targeted to an endothelial integrin involved in neoangiogenesis was compared to DCE-US and immunochemistry to assess the early response of three different therapeutic agents in renal cell carcinoma. Human A498 renal cells carcinoma was subcutaneously inoculated into 24 nude mice. Mice received either phosphate-buffered saline solution, sunitinib, everolimus, or bevacizumab during 4 days. DCE-US and molecular MRI targeting αvß3 were performed at baseline and 4 days after treatment initiation. PI, AUC, relaxation rate variations ΔR2⁎, and percentage of vessels area quantified on CD31-stained microvessels were compared. Significant decreases were observed for PI and AUC parameters measured by DCE-US for bevacizumab group as early as 4 days, whereas molecular αvß3-targeted MRI was able to detect significant changes in both bevacizumab and everolimus groups. Percentage of CD31-stained microvessels was significantly correlated with DCE-US parameters, PI (R = 0.87, p = 0.0003) and AUC (R = 0.81, p = 0.0013). The percentage of vessel tissue area was significantly reduced (p < 0.01) in both sunitinib and bevacizumab groups. We report an early detection of neoangiogenesis modification after induction of targeted therapies, using DCE-US or αvß3-targeted MRI. We consider these outcomes should encourage clinical trial developments to further evaluate the potential of this molecular MRI technique.


Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Molecular Imaging/methods , Molecular Targeted Therapy/methods , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Bevacizumab/pharmacology , Bevacizumab/therapeutic use , Carcinoma, Renal Cell/blood supply , Carcinoma, Renal Cell/drug therapy , Cell Line, Tumor , Everolimus/pharmacology , Everolimus/therapeutic use , Heterografts , Humans , Indoles/pharmacology , Indoles/therapeutic use , Magnetic Resonance Imaging/methods , Male , Mice , Pyrroles/pharmacology , Pyrroles/therapeutic use , Sunitinib , Treatment Outcome
3.
J Health Soc Policy ; 15(3-4): 53-67, 2002.
Article in English | MEDLINE | ID: mdl-12705464

ABSTRACT

For the last decade the federal government has provided financial support through Title IV-E of the Social Security Act to schools of social work to provide professional education in child welfare. This study looks at the first four cohorts of graduates who received IV-E funding from one school of social work. Data on MSW graduates from 1993-1996 (N = 73), as well as survey responses (N = 32), were analyzed to ascertain dimensions of their career development in, and contributions to, child welfare social work. Results indicate that the vast majority of graduates funded by IV-E dollars became employed in and stayed in child welfare focused social work, with a strong percentage in public child welfare services, and that these social work-educated social workers are actively involved in shaping the practice, policies and administration of child welfare services.


Subject(s)
Career Mobility , Child Welfare , Public Health Administration , Social Work/education , Child , Cohort Studies , Education, Graduate/economics , Employment/statistics & numerical data , Ethnicity , Female , Financing, Government , Humans , Leadership , Male , Minnesota , Social Security/legislation & jurisprudence , Surveys and Questionnaires , Training Support/legislation & jurisprudence , United States , Workforce
SELECTION OF CITATIONS
SEARCH DETAIL